Testosterone Cypionate: Renal Protection or Renal Risk?

Testosterone cypionate is an injectable, long-acting ester of testosterone (an androgen, class: androgens/anabolic-androgenic steroids) approved by the FDA for testosterone replacement therapy in men with hypogonadism confirmed by low serum testosterone and clinical symptoms. It is not the same compound as testosterone enanthate, testosterone undecanoate, or compounded topical formulations, though renal effects discussed here draw partly on studies of related esters.

The useful question is not whether testosterone cypionate is "good" or "bad" for the kidneys, but at what dose and in what patient. At physiologic replacement doses used for approved hypogonadism treatment, the best available randomized evidence shows no signal of kidney harm, and there are plausible, dose-dependent mechanisms (erythropoietin stimulation, anti-inflammatory signaling) by which it may help specific subgroups such as men with chronic kidney disease (CKD) and anemia. At supraphysiologic doses taken outside medical supervision, biopsy-confirmed kidney injury, specifically focal segmental glomerulosclerosis (FSGS), is a documented and serious risk. The dose is doing almost all of the work in this story, and a reader who treats "testosterone and kidneys" as one answer will get the wrong one for their situation.

What testosterone cypionate does to the kidneys

Testosterone cypionate is an esterified androgen that hydrolyzes to free testosterone after intramuscular injection, sustaining serum levels for roughly 7 to 14 days. Its renal effects are not a single action but several competing pathways whose net effect depends heavily on dose, baseline kidney function, comorbidities, and duration of exposure.

At replacement doses targeting serum testosterone in the normal physiologic range, the predominant renal signals described in the literature are anti-inflammatory and vasodilatory. At doses used in non-medical bodybuilding contexts, which can run many multiples of the therapeutic range, the dominant signals reported are glomerular hypertension, podocyte injury, and proteinuria.

Androgen receptors in renal tissue

Androgen receptors are expressed throughout the nephron, including the proximal tubule, glomerular mesangial cells, and podocytes (Quinkler et al.). In animal and cell-culture models, androgen receptor activity in the proximal tubule and podocytes has been linked to sodium handling and to attenuation of podocyte injury under oxidative stress. These are mechanistic, largely preclinical observations; they have not been directly confirmed in human kidney biopsy studies, and readers should treat them as plausible biology rather than established clinical fact.

The erythropoiesis-kidney axis

Testosterone stimulates erythropoietin (EPO) secretion from peritubular interstitial cells in the kidney, the same tissue that raises EPO output in response to hypoxia. Hematocrit increases are a well-documented, dose-related effect of testosterone therapy, and this is the basis of the Endocrine Society's recommendation to monitor hematocrit during treatment (Bhasin et al., 2010 guideline). In men with anemia related to CKD, this same effect has been proposed as a mechanism by which testosterone might reduce the dose of erythropoiesis-stimulating agents needed, though this remains a plausible extrapolation rather than a demonstrated clinical outcome from a large trial.

What the best randomized data show: the T-Trials

The most rigorous randomized controlled evidence for testosterone-cypionate use in aging men comes from the Testosterone Trials (T-Trials), a landmark study published in the New England Journal of Medicine in 2016 (Snyder et al., 2016). This multi-site investigation included 790 participants over age 65 whose baseline testosterone levels measured below 275 ng/dL, with outcomes measured across sexual performance, physical capability, and overall energy levels.

Participants received testosterone gel titrated toward a target of 500 ng/dL, or matching placebo, for 12 months. Sexual function and 6-minute walk distance improved significantly in the testosterone group. This is trial-level evidence for those specific outcomes, in a topical formulation, in men aged 65 and older with confirmed low testosterone; it does not directly establish equivalent effects for testosterone cypionate injections or for younger men.

The T-Trials were not designed or powered to evaluate renal endpoints, and no eGFR analysis was pre-specified. Adverse event surveillance did not report a signal for acute kidney injury or accelerated CKD progression at 12 months. The clearest renal-adjacent safety finding was polycythemia: hematocrit above 54% occurred more often in the testosterone group than in placebo. That finding is the main reason hematocrit monitoring, rather than routine kidney imaging or biopsy, is the standard safety check during TRT.

The Endocrine Society's 2018 clinical practice guideline addresses hematocrit monitoring directly, recommending baseline hematocrit assessment, rechecks at 3 to 6 months and then annually, and dose reduction or treatment pause if hematocrit rises above roughly 54%, with evaluation for contributing causes such as sleep apnea (Bhasin et al., 2018). The exact wording of the guideline's recommendation should be checked against the primary document before being quoted verbatim in any clinician-facing material; this article summarizes rather than quotes it.

Anabolic steroid nephropathy: a distinct, dose-driven entity

Anabolic steroid nephropathy is not a risk of testosterone cypionate at prescription doses. It is a pathological entity described in people using androgens at supraphysiologic doses, typically in non-medical performance-enhancement contexts.

Focal segmental glomerulosclerosis in case-series data

A case series published in the Journal of the American Society of Nephrology described biopsy-proven FSGS in bodybuilders with a history of prolonged, high-dose androgen use (Herlitz et al., 2010). The reported doses were far above the 100 to 200 mg weekly range used in standard TRT. Specific figures for proteinuria and eGFR at presentation vary by report; readers and clinicians who need exact numbers for a specific patient conversation should verify them against the primary paper rather than relying on a secondhand summary, including this one.

Why high doses appear to injure the kidney

Several mechanisms are proposed to converge at supraphysiologic androgen concentrations:

1. Glomerular hypertrophy and hyperfiltration. Greater lean body mass raises metabolic demand on the kidney, and a compensatory rise in single-nephron GFR is thought to drive glomerular scarring over years. Much of the direct evidence for this pathway in androgen users comes from case reports and small series rather than controlled studies (Parente et al., case report).
2. Direct podocyte stress. Androgen receptor overstimulation is hypothesized to disrupt podocyte cytoskeletal integrity, consistent with the FSGS pattern seen on biopsy (Herlitz et al.).
3. Dyslipidemia-associated vascular injury. Supraphysiologic androgen use is associated with substantial HDL suppression and adverse lipid changes that may contribute to endothelial and glomerular injury over time (Baggish et al.).

Does kidney function recover after stopping?

Case-series follow-up after androgen cessation has generally shown partial, not complete, improvement in proteinuria and eGFR, with some patients progressing further despite discontinuation. This supports treating supraphysiologic androgen-associated kidney injury as a serious and only partially reversible condition, not a benign, self-resolving one.

Testosterone cypionate in men with pre-existing CKD

Hypogonadism is more common in men with reduced kidney function than in the general population; this relationship is described in broader reviews of protein-energy wasting and endocrine changes in CKD (Carrero et al.). That review addresses metabolic and nutritional derangements in CKD generally and does not by itself establish a precise numeric relationship between eGFR category and testosterone deficiency prevalence; a reader who needs an exact prevalence figure should look for a dedicated cross-sectional study rather than relying on this general reference.

What can and cannot be said about benefit in CKD

Small studies and mechanistic work suggest testosterone's anti-inflammatory actions, including suppression of NF-kB signaling pathways relevant to uremic inflammation, could plausibly benefit men with CKD who are also hypogonadal (Kastarinen et al.). However, a dedicated, adequately powered randomized trial establishing that testosterone therapy stabilizes eGFR or slows CKD progression in men with CKD stages 3 to 5 was not identified in the sources supporting this article. Claims of a specific eGFR-stabilization effect at a specific CKD stage should be treated as unverified until a primary trial can be located and checked; this is flagged here rather than presented as settled.

Risks that CKD amplifies

Reduced kidney function changes the risk-benefit calculation in specific, mechanistically clear ways:

• Fluid retention. Testosterone's sodium-retaining, RAAS-stimulating effects are more consequential when the kidney's capacity to excrete a sodium load is already reduced, as in CKD stages 4 to 5.
• Thrombotic risk from polycythemia. Hematocrit elevation is more concerning in CKD patients, who already carry a prothrombotic tendency from uremia and dyslipidemia.
• Pharmacokinetics. Testosterone cypionate is hepatically metabolized and its pharmacokinetics are not substantially altered by CKD itself, but the downstream effects on volume status and erythropoiesis are amplified in reduced renal function.

Renal risk-stratified decision framework for testosterone cypionate

This is a site-authored organizing framework based on the mechanisms and monitoring standards above. It is not a validated clinical algorithm and does not replace nephrology or endocrinology judgment for an individual patient.

The row a reader falls into should determine whether this is a conversation to have with a primary care clinician, an endocrinologist, or a nephrologist, not a decision to make from an article.

Fluid retention and blood pressure: a real but usually modest effect

Testosterone promotes renal sodium retention through mineralocorticoid receptor activation at higher androgen concentrations and through stimulation of the renin-angiotensin-aldosterone system. In men with normal kidney function, modest early weight gain from fluid is common and generally benign. In men with hypertension or CKD, the same sodium retention has more room to matter, since their capacity to compensate is reduced.

Cardiovascular safety data for testosterone therapy, including from the large TRAVERSE trial program, address cardiovascular outcomes broadly and are relevant context for weighing hemodynamic risk in men with cardiovascular or renal disease (Lincoff et al., 2023). A precise, pooled estimate of testosterone's average effect on systolic blood pressure across randomized trials was not confirmed from the sources available for this article; a specific numeric blood-pressure effect size should not be treated as established without checking a dedicated meta-analysis directly.

Practical implication

Blood pressure should be checked at every visit during at least the first several months of therapy in men with CKD or hypertension, and existing RAAS-blocking therapy (ACE inhibitor or ARB) should generally be continued rather than discontinued when starting TRT in a patient with proteinuric CKD. This is a site judgment based on the mechanisms above, not a quoted guideline recommendation.

Monitoring: what to check and when

Monitoring is what converts testosterone cypionate from a drug with theoretical renal risk into one that is manageable in practice. The framework below follows the general structure of the Endocrine Society's 2018 guideline, with nephrology-relevant additions noted as such.

Baseline, before the first injection

• Serum total and free testosterone, LH, FSH to confirm hypogonadism
• Complete blood count and hematocrit
• Comprehensive metabolic panel including creatinine and eGFR (CKD-EPI equation)
• Urine albumin-to-creatinine ratio
• Seated blood pressure after rest
• PSA if age 40 or older
• Lipid panel

First 6 months

• Testosterone trough level after initial titration
• Hematocrit at 3 and 6 months
• Creatinine and blood pressure at 3 months
• uACR at 6 months, sooner if baseline was elevated

Ongoing

• Annual full panel once stable
• Every 6 months instead of annually for men with CKD stage 3 or higher, or a uACR above 30 mg/g

Why cystatin C matters in this specific population

Standard creatinine-based eGFR tends to overestimate kidney function in men with higher muscle mass, which is common in men on testosterone therapy, because creatinine is a muscle metabolism byproduct. Cystatin C is not affected by muscle mass and provides a more reliable eGFR estimate in this context (Inker et al., 2012). The KDIGO 2022 guideline supports confirmatory cystatin C-based eGFR testing when a creatinine-based result alone would change management (KDIGO 2022).

Special populations

Dialysis

Men on hemodialysis commonly have lower testosterone than age-matched men without kidney disease, related to uremic suppression of the hypothalamic-pituitary-gonadal axis. Small studies have explored testosterone therapy for anemia, nutritional status, and quality of life in this population without reported worsening of residual kidney function, which is typically minimal at this stage regardless. Fluid balance is the primary safety concern to track during titration.

Kidney transplant recipients

Testosterone cypionate is not inherently contraindicated after kidney transplantation, but it can interact with calcineurin inhibitors. Testosterone may modestly raise tacrolimus levels through CYP3A4 competition, based on narrative review-level evidence rather than a dedicated interaction trial (Dumitrascu et al.). Rechecking tacrolimus trough levels a few weeks after starting TRT is a reasonable precaution to discuss with the transplant team.

Active nephrotic syndrome

Active nephrotic syndrome with heavy proteinuria is a relative contraindication to starting TRT. Testosterone's sodium-retaining effect can worsen edema, and the pro-thrombotic state of nephrotic syndrome is compounded by testosterone's effect on hematocrit. This is a mechanism-based caution rather than a finding from a dedicated trial in this specific population.

What is established, what is plausible, and what is not established

Established: Testosterone therapy raises hematocrit in a dose-related way, and hematocrit above roughly 54% is an accepted trigger for dose adjustment or pause. Randomized trial safety surveillance (T-Trials) did not identify an acute kidney injury or CKD-progression signal at 12 months in older hypogonadal men on a topical formulation. Supraphysiologic androgen use is associated with biopsy-confirmed FSGS in case-series data.

Plausible but not established: That testosterone therapy meaningfully stabilizes eGFR or reduces CKD progression in men with CKD stages 3 to 5, that erythropoietin stimulation from testosterone meaningfully reduces ESA requirements in dialysis patients, and that androgen receptor effects on podocytes seen in preclinical models translate into measurable protection in human kidneys. These are reasonable hypotheses supported by mechanism and small or indirect studies, not confirmed findings from adequately powered trials.

Not established from the sources reviewed here: A precise pooled blood-pressure effect size for testosterone therapy across randomized trials, a precise prevalence ratio for hypogonadism by CKD stage from a specific cross-sectional study, and exact biopsy-series statistics (patient counts, dose thresholds, proteinuria and eGFR values) that would need to be checked against the original FSGS case series before being cited as precise numbers in patient-facing material.

If you have CKD and are considering or currently taking testosterone therapy, the practical next step is a conversation with your prescribing clinician, and ideally your nephrologist if you are stage 3 or beyond, about your individual eGFR trajectory, blood pressure trend, and hematocrit, rather than relying on population-level averages from any single article.

Seek urgent care for sudden swelling, a marked drop in urine output, chest pain, sudden shortness of breath, or a hematocrit result far above your prior baseline reported by your clinician, since these can reflect fluid overload, thrombosis, or a rapidly rising red cell mass that needs prompt evaluation.